Products for Research Use Only

Isatuximab

CAT: 0804-HY-P9976-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P9976-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM) . Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions[1][2].
CAS Number
1461640-62-9
Product Name Alternative
Ch38SB19; hu38SB19; SAR-650984
UNSPSC
12352203
Target
Apoptosis
Type
Inhibitory Antibodies
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/isatuximab.html
Purity
98.5
Solubility
H2O
Smiles
[Isatuximab]
Molecular Weight
(145.2 kDa)
References & Citations
[1]Dhillon S. Isatuximab: First Approval [published correction appears in Drugs. 2020 May 23; :]. Drugs. 2020;80 (9) :905-912.|[2]Attal M, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM) : a randomised, multicentre, open-label, phase 3 study [published correction appears in Lancet. 2019 Dec 7;394 (10214) :2072]. Lancet. 2019;394 (10214) :2096-2107.
Shipping Conditions
Blue Ice
Storage Conditions
Store at 4°C for 2 years, do not freeze
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched